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ported. In addition, a case of central DI and panhypopituitarism 
due to pituitary metastasis from breast adenocarcinoma has 
been reported, but rarely confirmed pathologically7,11,15).
Here, we report a pituitary mass found in a patient after sur-
gery and chemotherapy for breast cancer. The patient under-
went a surgical tumor removal via sublabial transsphenoidal 
approach and metastasis from breast invasive ductal adenocar-
cinoma was confirmed pathologically. This case is presented 
with a literature review.
CASE REPORT
A 65-year-old female was referred to the Department of Neu-
rosurgery from the Department of General Surgery with pro-
gressive bitemporal hemianopsia and loss of visual acuity in the 
left eye for three months. She had undergone a left radical mas-
tectomy for invasive ductal carcinoma five years earlier and re-
ceived four cycles of adjuvant chemotherapy using adriamycin/
cyclophosphamide (AC) and radiation therapy. Twenty-eight 
months postoperatively, there was local left thoracic wall recur-
rence, and she underwent four additional cycles of docetaxel 
chemotherapy. Nine months later, after she developed new back 
pain, a bone scan and spine magnetic resonance imaging (MRI) 
INTRODUCTION
Although malignant tumors often metastasize to the brain, 
metastases to the pituitary gland are uncommon and constitute 
only 3-5% of all cases; primary sites usually include the lung, 
breast, and gastrointestinal tract13,14). Metastases occur in the 
6th or 7th decade of life and this age range does not differ ac-
cording to gender13,14). The most common symptom in patients 
with pituitary metastases, unlike those with primary pituitary 
tumors, is central diabetes insipidus (DI), followed by anterior 
hypopituitarism, visual loss, and central nervous system (CNS) 
disorders8,12). However, it is difficult to diagnose pituitary me-
tastases, as the symptoms are nonspecific and the radiological 
differences from primary tumors are trivial5). Although differ-
entiating whether a pituitary tumor is primary or secondary is 
crucial in making a treatment plan, it is difficult to make a diag-
nosis without pathological confirmation. If a tumor in the pitu-
itary gland is confirmed to be metastatic, local tumor control is 
planned to relive symptoms, and the prognosis depends on the 
site of the primary malignancy8,12).
In South Korea, pituitary metastases from hard palate adeno-
carcinoma, periampullary adenocarcinoma, renal cell carcino-
ma, malignant lymphoma, and lung carcinoma have been re-
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mass in the pituitary gland one month after the initial operation. 
Central DI occurred one week after the CyberKnife treatment, 
but improved with vasopressin. Following the CyberKnife treat-
ment, the patient’s hormone levels were within the normal rang-
es, so the vasopressin replacement was maintained (Table 1). 
The patient returned for follow-up five months after the initial 
surgery and four months after the CyberKnife surgery, with no 
signs of metastasis. Subsequently, she was lost to follow-up.　 
DISCUSSION
Metastatic spread of cancer to the pituitary gland is uncom-
mon, but may occur more commonly than pituitary adenoma, 
were performed, which showed multi-
ple metastases of breast cancer to the 
4th and 5th lumbar vertebrae, right sa-
crum, and pelvis. The patient received 
radiation therapy to the metastases ten 
times and was prescribed letrozole. She 
had also been taking medication for hy-
pertension.
Due to progressive left visual loss, 
brain MRI was performed. A 1.1×2.2×2 
cm pituitary mass was found, with in-
termediate signal intensity on T1- and 
T2-weighted images and a well-en-
hancing nature. The mass was dumbbell shaped, compressed 
the optic chiasm, and displaced the pituitary stalk to the left 
(Fig. 1). Blood and urine tests were all normal, except for ele-
vated prolactin measuring 42.60 ng/mL (Table 1). On visual 
field examination, bitemporal hemianopsia was noted with de-
creased visual acuity on the left side.
Although the patient had a history of multiple metastases 
from breast cancer, the MRI findings and laboratory results sug-
gested that the pituitary mass was a primary macroadenoma; 
therefore, we performed a surgical tumor removal via sublabial-
transsphenoidal approach. Since the intraoperative findings of 
the mass were similar to a benign pituitary macroadenoma, no 
frozen pathological examination was performed (Fig. 2).
The patient’s postoperative course was uneventful and the pro-
lactin level determined three days postoperatively was 10.50 ng/
mL, which was within the normal range (Table 1). Seven days 
postoperatively, her urine output increased to 130 mL hourly. A 
water restriction test was performed, and she was diagnosed 
with central DI. After administering vasopressin, the central DI 
improved and the left visual acuity improved both subjectively 
and objectively, from 0.16 preoperatively to 0.20 postoperatively.
The pathology report seven days postoperatively showed 
moderately differentiated adenocarcinoma; immunohistochem-
ical staining with MOC-31 was positive. The final diagnosis was 
that the tumor was metastasized from breast invasive ductal 
carcinoma (Fig. 3).
The patient underwent CyberKnife treatment for the remnant 
Fig. 1. Preoperative coronal view of T1 weighted image of sellar MRI (A), coronal view of T2 weighted image (B), coronal view of T1 Gadolinum en-
hanced image (C), sagittal view of T1 Gadolinum enhanced image (D). Images show the dumbbell shape pituitary mass with T1 intermediate, T2 in-
termediate and well enhancing nature, compressing the optic chiasm and invading the pituitary stalk. 
A B C D
Table 1. Hormonal tests results
Preoperation POD 3 POD 1 month Normal value
Cortisol (ug/dL)   9.35 22.36   1.82      4.5-21.1 
ACTH (pg/mL) 36.87 31.85 44.02            6-556.7 
LH (IU/L)   0.41   0.34 3.5 13.5-96 
FSH (IU/L)   2.59   2.41 5.1       27-129 
Estradiol-E2 (pg/mL) 31.57   6.13 <5.0       10-507 
HGH (ng/mL)   0.26   0.63   0.55       0-16 
Prolactin (ng/mL) 42.60 10.5   7.67       3.5-17.9 
TSH (mIU/L)   0.66   0.23   0.74     0.3-4.0 
ACTH : adrenocorticotripic hormone, LH : luteinizing hormone, FSH : follicle stimulating hormone, HGH : human 
growth hormone, TSH : thyroid stimulating hormone, POD : postoperative day
Fig. 2. Pituitary mass during the operation. The contents and colors 
were just similar with pituitary adenoma. 96
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es with pituitary metastasis, Komninos et al.5) reported that MRI 
may demonstrate an isointense or hypointense mass on T1-
weighted images with a high-intensity signal on T2-weighted 
images, homogeneous enhancement with gadolinium and an 
absent high-signal intensity for the posterior lobe on T1-weight-
ed images, a rapid increase of a sellar tumor with aggressive in-
filtration of adjacent tissues, or a dumbbell-shaped intrasellar 
and suprasellar tumor. Based on this report and our findings, a 
well-enhancing pituitary mass with stalk displacement suggests 
pituitary metastasis.
Although there have been several reports on sellar metastasis 
in South Korea, most of the cases presented with extensive in-
volvement in adjacent tissues or multiple brain metastasis7,15). 
Diagnoses of pituitary metastases with those radiological find-
ings and previous history of malignancy are not troublesome. 
However, findings in present case were more similar with those 
of primary adenoma, as the first symptom was bitemporal hemi-
anopsia rather than hormonal symptoms, and radiologic find-
ing was a single dumbell-shaped pituitary mass rather than 
multiple brain metastasis or extensive involvement of adjacent 
tissues. Therefore, physician should bear in mind the additional 
historical information to suspect pituitary metastasis, such as 
rapid onset and progression of symptom, unsuccessful treat-
ment with bromocriptine, increased age and history of malig-
nancy15).
The treatment for pituitary metastasis is usually conservative, 
ranging from surgical removal, radiation surgery, or systemic 
chemotherapy, focusing on the extent and condition of the pri-
mary tumor. When visual symptoms are present, as in our case, 
surgical intervention can improve the symptoms1,12).
Nevertheless, survival does not differ between groups under-
going surgical intervention to remove the metastatic mass ver-
sus no surgery8). That is, the prognosis of pituitary metastasis 
depends mainly on the extent of the primary tumor, rather than 
the mass in the pituitary gland. The reported life expectancy 
ranges from 6 to 22 months. In cases with pituitary stalk inva-
occurring in 3-5% of the patients with carcinoma14). In females, 
the most likely source of pituitary metastasis is the breast, while 
in men, metastases tend to be from the lung14). Two thirds of 
such tumors originate from these primary sites. In addition, gas-
trointestinal tract, prostate, kidney, thyroid, and pancreas prima-
ry tumors are possible sources of pituitary metastases13). In 53-
100% of cases, the primary sites are discovered simultaneously 
with the pituitary metastases both clinically and radiologically8).
The routes of metastasis to the pituitary gland include hema-
togenous spread or via direct invasion through the skull base. 
The former is the main pathway. The most commonly involved 
site is the posterior lobe of the hypophysis (69-79%), followed 
by the anterior hypophysis, both the anterior and posterior hy-
pophysis, and the stalk13). Previous studies have reported that 
DI is common when the posterior hypophysis is involved, and 
anterior hypophysis dysfunction, cranial nerve dysfunction, 
headache, and hyperprolactinemia can occur4,8,12). DI develops 
with involvement of the hypophysis, where antidiuretic hor-
mone (ADH) is produced, or the pituitary stalk, where ADH is 
delivered. Since DI is a very rare symptom in pituitary adeno-
ma, manifesting in less than 1%, it is the most important clini-
cal manifestation differentiating a metastatic tumor from a pri-
mary pituitary adenoma5,10). However, in a series of 52 patients 
with pituitary metastasis, Heshmati et al.3) found that visual im-
pairment (i.e., a visual field defect or extraocular palsy) was the 
presenting complaint in 56% of the subjects. DI signaled pitu-
itary involvement in 40% of the patients in their series3). In our 
case, the patient’s initial complaint was of a visual field defect, 
with no hormonal dysfunction; therefore, we presumed that the 
pituitary mass was a primary adenoma.
Although radiological diagnostic modalities have been devel-
oped, computed tomography (CT) is still insufficient for differ-
entiating benign and malignant masses. An MRI study revealed 
that findings such as a loss of high signal intensity in the poste-
rior hypophysis in T1-weighted images or hypertrophy of the 
pituitary stalk suggest metastases9). In a meta-analysis of 70 cas-
Fig. 3. Microscopic finding (HE, ×100).  Characteristic findings of adenocarcinoma consist with invasive proliferation of cancer cell foci, formation of ductal 
structures by cancer cells were seen (A), immunohistochemical staining with MOC-31, which is a marker for adenocarcinoma showed positive (B).
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tomatic metastases to the pituitary infundibulum resulting from prima-
ry breast cancer. Int J Clin Oncol 10 : 191-194, 2005
7. Kwak JW, Jie BS, Hong SH, Kim JH, Lee SH, Jo JH, et al. : A case of pitu-
itary metastasis of breast cancer presenting as diabetes insipidus and 
panhypopituitarism. J Korean Endocr Soc 22 : 125-129, 2007
8. Morita A, Meyer FB, Laws ER Jr : Symptomatic pituitary metastases. J 
Neurosurg 89 : 69-73, 1998
9. Moses AM, Clayton B, Hochhauser L : Use of T1-weighted MR imaging 
to differentiate between primary polydipsia and central diabetes insipi-
dus. AJNR Am J Neuroradiol 13 : 1273-1277, 1992
10. Ruelle A, Palladino M, Andrioli GC : Pituitary metastases as presenting 
lesions of malignancy. J Neurosurg Sci 36 : 51-54, 1992
11. Shin ET, Lee EJ, Kim KR, Lee KM, Bae HD, Lee KS, et al. : A case of pi-
tuitary metastasis from periampullary carcinoma. J Korean Soc Endo-
crinol 8 : 88-93, 1993
12. Sioutos P, Yen V, Arbit E : Pituitary gland metastases. Ann Surg Oncol 3 : 
94-99, 1996
13. Teears RJ, Silverman EM : Clinicopathologic review of 88 cases of carci-
noma metastatic to the putuitary gland. Cancer 36 : 216-220, 1975
14. Weil RJ : Pituitary metastasis. Arch Neurol 59 : 1962-1963, 2002
15. Yi HJ, Kim CH, Bak KH, Kim JM, Ko Y, Oh SJ : Metastatic tumors in 
the sellar and parasellar regions: clinical review of four cases. J Korean 
Med Sci 15 : 363-367, 2000
sion, the prognosis is usually poorer, i.e., 2-4 months2,6).
In this case, the MRI findings and primary symptoms were 
not enough to differentiate the sellar metastasis from primary 
pituitary adenoma. The ophthalmologic symptoms improved 
after surgical and CyberKnife treatment for the pituitary metas-
tasis. Although surgical intervention does not improve life ex-
pectancy, this case proved that surgery can improve the symp-
toms caused by pituitary metastasis, as previously reported15).
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